Cesca Therapeutics develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. Co. develops and supplies automation technologies for the isolation, purification and storage of stem cells for the cord blood banking industry. Through its ThermoGenesis Corp. subsidiary, Co. provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress platform under development for bio-manufacturing for immuno-oncology applications. Co. is also developing autologous cell-based therapies that address needs in the vascular and orthopedic markets. The KOOL average annual return since 2024 is shown above.
The Average Annual Return on the KOOL average annual return since 2024 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KOOL average annual return since 2024 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KOOL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|